We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
No offence mate, but if you just use a dictionary and look up current liabilities, it means liabilities due within 12 months.
"Current liabilities are a company's debts or obligations that are due within one year or within a normal operating cycle."
You owe Jimzi an apology, since all the liabilities AMP have baring a few million are due by December this year.
Too obvious quoting RNS figures?
Too obvious Jimzi….filtered.
So you’ve read the interims ?? Don’t dismiss my comments. You asserted I was patronising. Tell me current and total liabilities please.
Okay....you're either short or an MM. Nite Jimzi!
If you can’t read that all their liabilities are current, then you better get the half year financials changed cause it’s there in black and white . There’s usd 8m CPNs - they will convert at 3 p. Effect? The mms are completely neutral- they don’t care as with all other AIM stocks.
As an example.....I take out a £200K mortgage. Yes that is debt, and I need to pay £800 a month.
That £800 is a current liability. As long as I serve the mortgage, the whole amount due does not become current. If the bank foreclose.....I'm f...ed. The whole amount becomes current.
As long as I keep working and pay the current liability of £800 per month....everything is cool....but hey I only have a car and £1000 in the bank, Jesus.....my debt position is minus £190K+. Sequestrate me now!
That's not how it works and that is why AMP have renegotiated terms, pushing liabilities away from being current liabilities.
This is the angle MM's are taking (on this board) to have you sell your holding. Yip, if invested you are at risk....if the FDA answer is no, you will lose 75%......but that loss will have absolutely nothing to do with liabilities, current or otherwise.
IMHO DYOR
Current liabilities are total liabilities. Read the financials ffs
Below from https://www.thestreet.com/story/11635922/1/amarin-prepping-for-fda-approval-decision.html may be of interest What time will the FDA decision be announced? Impossible to say. We may hear in the middle of the day, like we did Friday with Onyx Pharmaceuticals ( ONXX), or not until evening as with Vivus ( VVUS - Get Report). If you're trading the Amarin approval decision, my best advice is to be ready for news any time after noon EDT. And don't forget that Amarin may decide to halt trading at some point Thursday ahead of the announcement.
Andre01 it cuts both our ways. Plenty on here doing the ramping too without substance. Difference is NE does add logic, so rightly or wrongly, agree if disagree, it’s got something behind it, rather than some of the pointless ramps on here with nothing behind them bar hot air Let’s see what comes tomrorow GL
If like me you believe motif will get the Nod. It’s worth investing in here for the leverage. Like it’s aleeady been pointed out. This should bag on the results due for Motif. If Motif doesn’t get approval. This is worthless. Worth a gamble.
Just for completeness. Current liabilities are not total liabilities. In the event of a yes, you will need to re-think that paradigm.
Don't agree. But hey, proof will be the eating of the pudding. Could lose loads if answer is no.
However, no indication of requisitions over the past 7 months for application, viewed and revised by MTFB and AMP. FDA advise the application is complete (apparently). Its not as if this drug does not have its probs. Cardiac contras are present....but for renal …..there are no contras. Cardiac would need managed IMHO. So for competitor drugs, they will be used first (if no renal issues….cheaper) and if resistance occurs, ours will be the go to drug....last resort Though renal amounts to 26% if you add on current and projected resistance to competitors, then we will likely take 40+% of the market in first instance.
All depends upon FDA approval....though it may be with monitoring side effects.
Take your pick……..but at these numbers..... liabilities whether current or otherwise, ….is scare mongering. Is the scare mongering working.....no!
Lol. Pmsl. What is the debt figure then ?
Up is people deramping and basically reposting the same shite 50 times a day (northernexplorer is a good example) as others have explained not all of it is debt but he keeps spouting the same figure as he is clearly agenda driven.
Just out of curiosity.. there's no mention of projected future income. Assuming the FDA give us the thumbs up and we enter a plus 2 billion market.. what is our forecast?
Total liabilities are current liabilities. The stark difference is nil . ( easy to check) You ain’t checked anything. 8m CPNs - what does that do to SP? A bb is for investors who discuss the highs and lows over the medium term. You don’t understand the numbers. Your praying for a spike. Fair dos, just don’t pump crap.
Nope......DYOR
Binary.
FDA yes or no. Yes....moon. No.....in the pits. Take you're pick.
Gut will be telling you either or, has nothing to do with current or non current liabilities. MM project fear.
;-)
Aviz, care to elaborate on your understanding in that case?
Assumption that others don't understand the numbers here is a little patronising.
There is a stark difference between liabilities and current liabilities. If you don't understand watch the SP over the next week following (hopefully) MTFB approval, and sit down and acknowledge that you don't understand.
You’ve all had over a week the dissect the figures and what ? Total liabilities but then add in directors loans to justify your figure. Joke. Total is total. 8m of liabilities is CPNs at 3 p so they won’t be repaid in cash so it’s not debt. But Dilution , yes. Peeps throwing cash around without reading ( or understanding) the financials. This is a long termer at 1 p ( with risk of course) but very considerable upside indeed if you think iclipram smahes the market - which being a non resistant AB - it’s very likely. And POLX looks good but later BB as per , v little proper analysis .
About Iclaprim Iclaprim is a novel investigational antibiotic with a targeted Gram-positive spectrum of activity. In contrast to commonly used broad-spectrum antibiotics, this “precision medicine approach” is consistent with antibiotic stewardship principles which, among other things, seek to reduce the inappropriate use of broad-spectrum products to avoid the build-up of resistance and to lessen the impact on the microbiome of the patient. Iclaprim has a different and underutilised mechanism of action compared to most other antibiotics. Following positive results from two Phase 3 trials (REVIVE-1 and REVIVE-2), a New Drug Application (NDA) has been submitted to the U.S. Food & Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI). To date, iclaprim has been studied in over 1,400 patients and healthy volunteers. Clinical and microbiological data indicate that iclaprim has a targeted Gram-positive spectrum of activity, low propensity for resistance development and favourable tolerability profile. In clinical studies, iclaprim has been administered intravenously at a fixed dose with no dosage adjustment required in patients with renal impairment or in obese patients. The iclaprim fixed dose may, if approved, help reduce the resources required in hospitals since dosage adjustment by health care professionals is avoided and overall hospital treatment costs may be lower, especially in patients with renal impairment. Many standard of care Gram-positive antibiotics are not suitable for hospitalised ABSSSI patients with renal impairment due to efficacy and/or safety issues.
Spot on DP
The accountants do things differently. Waiting for an entry at 1.7p probably.
Tomorrow pre-rns is last chance to buy cheap. Sure to be some shaking.
If RNS lands and it's approval, don't plan to buy in the 1s. And certainly not when MTFB is at 114p lol Good joke